<div id="readability-page-1"><div><p>It's shaping up to be a tough period for <strong>Alibaba Health Information Technology Limited</strong> (HKG:241), which a week ago released some disappointing yearly results that could have a notable impact on how the market views the stock.      Alibaba Health Information Technology missed earnings this time around, with CN¥34b revenue coming in 2.6% below what the analysts had modelled. Statutory earnings per share (EPS) of CN¥0.12 also fell short of expectations by 14%.     Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company.  We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.</p><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p><figure><img height="1048" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/4481114-earnings-and-revenue-growth-1-dark-2/1778979887711?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1642" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/4481114-earnings-and-revenue-growth-1-dark-2/1778979887711"/><figcaption>SEHK:241 Earnings and Revenue Growth May 17th 2026</figcaption></figure><p> After the latest results, the 14 analysts covering Alibaba Health Information Technology are now predicting revenues of CN¥39.0b in 2027. If met, this would reflect a notable 14% improvement in revenue compared to the last 12 months.       Per-share earnings are expected to rise 9.9% to CN¥0.13.        In the lead-up to this report, the analysts had been modelling revenues of CN¥39.5b and earnings per share (EPS) of CN¥0.17 in 2027.        So there's definitely been a decline in sentiment after the latest results, noting the pretty serious reduction to new EPS forecasts.    </p><p><span> Check out our latest analysis for Alibaba Health Information Technology </span></p> <p> The consensus price target held steady at HK$6.38, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future.        There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business.   The most optimistic Alibaba Health Information Technology analyst has a price target of HK$12.43 per share, while the most pessimistic values it at HK$3.60.   So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate.  As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.    </p> <p> One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing.     The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 14% growth on an annualised basis. That is in line with its 14% annual growth over the past five years.    Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 13% annually.  It's clear that while Alibaba Health Information Technology's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.     </p><h2>The Bottom Line </h2><p> The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Alibaba Health Information Technology.        They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry.       The consensus price target held steady at HK$6.38, with the latest estimates not enough to have an impact on their price targets.  </p><p> Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings.   At Simply Wall St, we have a full range of analyst estimates for Alibaba Health Information Technology going out to 2029, and you can see them free on our platform here.. </p><p> You can also see our  analysis of Alibaba Health Information Technology's Board and CEO remuneration and experience, and whether company insiders have been buying stock. </p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

00241

159929

510660

512010

<p>Alibaba Health Information Technology Limited reported disappointing earnings, missing EPS expectations by 14% and revenue by 2.6%. Analysts have revised their forecasts, predicting a revenue increase to CN¥39.0b in 2027, reflecting a 14% growth. The consensus price target remains at HK$6.38, despite a wide range of analyst estimates. Concerns arise from reduced EPS estimates, indicating potential business challenges ahead, while revenue growth is expected to align with industry trends.</p>

Simplywall

ALI HEALTH

China Universal 800 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Earnings Miss: Alibaba Health Information Technology Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts